(MedPage Today) — BERLIN — An investigational oral drug currently under review with the FDA showed durable antitumor activity in patients with HER2-mutant advanced non-small cell lung cancer (NSCLC), findings from an international phase I/II…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118084
Author :
Publish date : 2025-10-22 17:31:00
Copyright for syndicated content belongs to the linked Source.
